Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus TRIMPEX 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus TRIMPEX 200.
CHLOROMYXIN vs TRIMPEX 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
200 mg orally once daily, or 100 mg orally twice daily.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
CHLOROMYXIN is not a recognized drug. No data available.
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with an additional 10-20% as hepatic metabolites excreted in bile and feces.
Category C
Category C
Antibiotic
Antibiotic